Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells.
Lehne
G
G
Department of Clinical Pharmacology, Institute for Surgical Research, The National Hospital, Rikshospitalet, Oslo, Norway.
De Angelis
P
P
Clausen
O P
OP
Rugstad
H E
HE
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D015250:Aclarubicin / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D003524:Cyclosporins / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D015251:Epirubicin / Q000494:pharmacology; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D003524:Cyclosporins; C066998:methoxy-morpholinyl-doxorubicin; D015251:Epirubicin; D015250:Aclarubicin; D004317:Doxorubicin; C070272:valspodar; D003630:Daunorubicin